Stefan Fichtner‐Feigl

This study investigates the immunomodulatory effects of SHP2-based vertical RAS pathway inhibition in pancreatic cancer, revealing both immune-activating and suppressive changes that evolve with treatment.

This study shows that membrane-localized xenoantigens enhance CD4+ T cell responses and improve anti-PD-1 therapy efficacy in pre-immunized mice, using OVA and VZV gE antigens.

This study identifies fatty acid-driven cytotoxicity in postoperative pancreatic fistula effluents and links it to cellular injury and transcriptional stress responses in anastomotic healing.

This study shows that dual SHP2/MEK inhibition in pancreatic cancer causes mitochondrial changes and ROS elevation, leading to a therapy-resistant state that can be targeted with GPX4 inhibition.